Daewon Pharmaceutical Co. Ltd. (003220) — Cash Flow Quality Index
Daewon Pharmaceutical Co. Ltd. (003220) has a Cash Flow Quality Index of -1.09x as of June 2026. Operating cash flow of ₩-4.39 Billion is below net income of ₩4.03 Billion, suggesting accrual-heavy earnings not yet converted to cash. Explore 003220 cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Daewon Pharmaceutical Co. Ltd. Cash Flow Quality Index (2011–2024)
Historical Cash Flow Quality Index for Daewon Pharmaceutical Co. Ltd. across 14 annual periods. Values consistently above 1.0x indicate high-quality earnings. See 003220 equity financing ratio to measure how much of total assets are equity-financed.
Annual Cash Flow Quality Index for Daewon Pharmaceutical Co. Ltd. (2011–2024)
Year-by-year earnings quality comparison for Daewon Pharmaceutical Co. Ltd.. For the full cash flow conversion analysis, see cash efficiency ratio of Daewon Pharmaceutical Co. Ltd..
| Year | Quality Index | Operating CF (KRW) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 3.21x | ₩30.04 Billion | ₩9.35 Billion | ▲ +48.5% |
| 2023 | 2.16x | ₩51.73 Billion | ₩23.92 Billion | ▲ +103.1% |
| 2022 | 1.07x | ₩33.33 Billion | ₩31.28 Billion | ▼ -68.4% |
| 2021 | 3.37x | ₩22.41 Billion | ₩6.65 Billion | ▲ +151.3% |
| 2020 | 1.34x | ₩24.95 Billion | ₩18.62 Billion | ▲ +18.1% |
| 2019 | 1.13x | ₩30.97 Billion | ₩27.29 Billion | ▼ -32.7% |
| 2018 | 1.69x | ₩40.03 Billion | ₩23.74 Billion | ▲ +324.6% |
| 2017 | 0.40x | ₩4.27 Billion | ₩10.74 Billion | ▼ -61.3% |
| 2016 | 1.03x | ₩20.79 Billion | ₩20.24 Billion | ▼ -29.6% |
| 2015 | 1.46x | ₩25.82 Billion | ₩17.69 Billion | ▲ +31.5% |
| 2014 | 1.11x | ₩17.45 Billion | ₩15.73 Billion | ▲ +10.9% |
| 2013 | 1.00x | ₩12.32 Billion | ₩12.32 Billion | ▼ -30.5% |
| 2012 | 1.44x | ₩13.83 Billion | ₩9.61 Billion | ▼ -24.3% |
| 2011 | 1.90x | ₩17.93 Billion | ₩9.44 Billion | — |